Citi lowered the firm’s price target on Solid Biosciences (SLDB) to $14 from $16 and keeps a Buy rating on the shares following data from the Phase 1/2 INSPIRE-DUCHENNE trial. The firm says microdystrophin expression after 90 days dropped.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating
- Solid Biosciences price target lowered to $9 from $10 at Barclays
- Solid Biosciences Reports Q3 2025 Results and Clinical Progress
- Solid Biosciences Reports Positive Interim Data on SGT-003